{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-22-000038","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.961278+00:00","generated_at":"2026-06-21T05:43:48.297177+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"QuidelOrtho appoints Kenneth Buechler as non-executive Chairman; Bryant remains CEO and becomes President","bullets":["Kenneth Buechler, Lead Independent Director, appointed non-executive Chairman effective Dec 11, 2022.","Douglas Bryant remains CEO and adds President role; Robert Bujarski and Michael Iskra appointed EVPs.","PSUs of ~$500k each (6,091 shares) granted to Bryant, Bujarski, Iskra; vesting by Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-22-000038","json":"https://secwatch.observer/filing/0001906324-22-000038.json","markdown":"https://secwatch.observer/filing/0001906324-22-000038.md","text":"https://secwatch.observer/filing/0001906324-22-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632422000038/0001906324-22-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632422000038/qdel-20221208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:43:48.297177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04f877c2a4","claim":"Michael S. Iskra was appointed as Executive Vice President at QuidelOrtho Corp.","evidence_excerpt":"Additionally, Mr. Bujarski, Chief Operating Officer, and Michael S. Iskra, Chief Commercial Officer, have both been appointed Executive Vice Presidents, in addition to continuing to serve in their existing leadership roles.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632422000038/0001906324-22-000038-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President"}],"fact_type":"executive_change"},{"claim_id":"160c20720f","claim":"Douglas C. Bryant was appointed as President at QuidelOrtho Corp.","evidence_excerpt":"The Board also appointed Mr. Bryant to serve, and succeed Robert J. Bujarski, as President of the Company, in addition to Mr. Bryant’s current role as Chief Executive Officer and a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632422000038/0001906324-22-000038-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"bbb7c4dc65","claim":"Robert J. Bujarski was appointed as Executive Vice President at QuidelOrtho Corp.","evidence_excerpt":"Additionally, Mr. Bujarski, Chief Operating Officer, and Michael S. Iskra, Chief Commercial Officer, have both been appointed Executive Vice Presidents, in addition to continuing to serve in their existing leadership roles.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632422000038/0001906324-22-000038-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President"}],"fact_type":"executive_change"},{"claim_id":"bff547ebc0","claim":"Kenneth F. Buechler was appointed as Chairman of the Board at QuidelOrtho Corp.","evidence_excerpt":"the Company’s Board of Directors (the “Board”) appointed Kenneth F. Buechler, Lead Independent Director, to serve, and succeed Douglas C. Bryant, as the Chairman of the Board (the “Chairman”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632422000038/0001906324-22-000038-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"11dec60714a2c82c50330bfd39914fa70f48487c","claim":"QuidelOrtho Corp: Board adopted an amendment and restatement of the Company’s Amended and Restated Bylaws, updating procedural and disclosure requirements for director nominations and business proposals, proxy card color requirements, and other updates (effective 2022-12-08).","evidence_excerpt":"On December 8, 2022, as part of its periodic review of corporate governance matters and in connection with the new U.S. Securities and Exchange Commission rules regarding universal proxy cards and certain recent amendments to the Delaware General Corporation Law (the “DGCL”), the Board adopted an amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of such date, in order to, among other things:","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632422000038/0001906324-22-000038-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-12-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}